Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) reached 44.45% versus a 1-year low price of $35.84. The stock was last seen 2.49% higher, reaching at $51.77 on Jun. 16, 2017. At recent session, the prices were hovering between $50.06 and $51.85. This company shares are 19.55% off its target price of $61.89 and the current market capitalization stands at $2.43B. The recent change has given its price a 2.88% lead over SMA 50 and -23.58% deficit over its 52-week high. The stock witnessed 2.45% gains, -3.52% declines and -2.52% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found AGIO’s volatility during a week at 3.51% and during a month it has been found around 4.02%.

Agios Pharmaceuticals, Inc. (AGIO) Top Holders

Institutional investors currently hold around $2.2 billion or 88.7% in AGIO stock. Look at its top three institutional owners. Fmr Llc owns $327.8 million in Agios Pharmaceuticals, Inc., which represents roughly 13.49% of the company’s market cap and approximately 14.91% of the institutional ownership. Similar statistics are true for the second largest owner, Wellington Management Group Llp, which owns 5,893,596 shares of the stock are valued at $305.11 million. The third largest holder is Bb Biotech Ag, which currently holds $147 million worth of this stock and that ownership represents nearly 6.05% of its market capitalization.

Agios Pharmaceuticals, Inc. 13F Filings

At the end of Mar reporting period, 83 institutional holders increased their position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by some 2,619,538 shares, 71 decreased positions by 1,033,636 and 26 held positions by 38,810,199. That puts total institutional holdings at 42,463,373 shares, according to SEC filings. The stock grabbed 23 new institutional investments totaling 298,286 shares while 26 institutional investors sold out their entire positions totaling 184,583 shares.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Insider Trades

Multiple company employees have indulged in significant insider trading. Agios Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Cantley Lewis Clayton Jr. has sold 2,000 shares of Agios Pharmaceuticals, Inc. (AGIO) in trading session dated Jun. 14, 2017. These shares are worth $101,740 and were traded at $50.87 each. The SEC filing shows that Schenkein David P performed a sale of 3,000 shares. The CEO disposed these shares by way of transaction on Jun. 07, 2017. The company’s shares were given away at $50.02 per share worth to an income of some $150,060 on account of Schenkein David P.

Director, Cantley Lewis Clayton Jr., sold 2,036 common shares of Agios Pharmaceuticals, Inc. (AGIO) in the open market. In a transaction dated May. 25, 2017, the shares were put up for sale at an average price of $47.1, raking in a sum of $95,896. After this sale, 231,434 common shares of AGIO are directly owned by the insider, with total stake valued at $11,981,338.

In the transaction dated May. 01, 2017, the great number of shares disposed came courtesy the CEO; Schenkein David P disposed a total of 3,000 shares at an average price of $50.06, amounting to approximately $150,180. The insider now directly owns 351,354 shares worth $18,189,597.

Agios Pharmaceuticals, Inc. (AGIO) Analyst Guide

Several analysts have released their opinion on Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), with 5 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.43 average brokerage recommendation.

Previous articleWhich insiders are selling Western Gas Partners, LP (NYSE:WES)?
Next articleAn End-of-Day Technical Review: Potash Corporation of Saskatchewan Inc. (POT), Information Services Group, Inc. (III)